Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes (SOUL)
In high-risk type 2 diabetes, once-daily oral semaglutide 14 mg cut major adverse cardiovascular events versus placebo in the SOUL trial, with no kidney benefit shown. PICO summary and expert commentary.
